|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Inoue-Choi M, Lazovich D, Prizment AE and
Robien K: Adherence to the World Cancer Research Fund/American
Institute for Cancer Research recommendations for cancer prevention
is associated with better health-related quality of life among
elderly female cancer survivors. J Clin Oncol. 31:1758–1766. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bardhan K and Liu K: Epigenetics and
colorectal cancer pathogenesis. Cancers (Basel). 5:676–713. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
vanEngeland M, Derks S, Smits KM, Meijer
GA and Herman JG: Colorectal cancer epigenetics: Complex
simplicity. J Clin Oncol. 29:1382–1391. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu FZ, Yu BH, Li DL, Ke HL, Guo XZ and
Xiao XY: PI3K expression and PIK3CA mutations are related to
colorectal cancer metastases. World J Gastroenterol. 18:3745–3751.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ye Q, Cai W, Zheng Y, Evers BM and She QB:
ERK and AKT signaling cooperate to translationally regulate
survivin expression for metastatic progression of colorectal
cancer. Oncogene. 33:1828–1839. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang J, Roberts TM and Shivdasani RA:
Targeting PI3K signaling as a therapeutic approach for colorectal
cancer. Gastroenterology. 141:50–61. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu M and Grady WM: Therapeutic targeting
of the phosphatidylinositol 3-kinase signaling pathway: Novel
targeted therapies and advances in the treatment of colorectal
cancer. Therap Adv Gastroenterol. 5:319–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Franke TF, Kaplan DR and Cantley LC: PI3K:
Downstream AKTion blocks apoptosis. Cell. 88:435–437. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Itoh N, Semba S, Ito M, Takeda H, Kawata S
and Yamakawa M: Phosphorylation of Akt/PKB is required for
suppression of cancer cell apoptosis and tumor progression in human
colorectal carcinoma. Cancer. 94:3127–3134. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Arcaro A and Guerreiro AS: The
phosphoinositide 3-kinase pathway in human cancer: Genetic
alterations and therapeutic implications. Curr Genomics. 8:271–306.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: Rationale and
promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Daouti S, Wang H, Li WH, Higgins B,
Kolinsky K, Packman K, Specian A Jr, Kong N, Huby N, Wen Y, et al:
Characterization of a novel mitogen-activated protein kinase kinase
1/2 inhibitor with a unique mechanism of action for cancer therapy.
Cancer Res. 69:1924–1932. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang SH, Sharrocks AD and Whitmarsh AJ:
MAP kinase signalling cascades and transcriptional regulation.
Gene. 513:1–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lange F, Franz B, Maletzki C, Linnebacher
M, Hühns M and Jaster R: Biological and molecular effects of small
molecule kinase inhibitors on low-passage human colorectal cancer
cell lines. Biomed Res Int. 2014:5686932014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cossa G, Gatti L, Cassinelli G, Lanzi C,
Zaffaroni N and Perego P: Modulation of sensitivity to antitumor
agents by targeting the MAPK survival pathway. Curr Pharm Des.
19:883–894. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
De Luca A, Maiello MR, D'Alessio A,
Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT
signalling pathways: Role in cancer pathogenesis and implications
for therapeutic approaches. Expert Opin Ther Targets. 16(Suppl 2):
S17–S27. 2012. View Article : Google Scholar
|
|
20
|
Gollob JA, Wilhelm S, Carter C and Kelley
SL: Role of Raf kinase in cancer: Therapeutic potential of
targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol.
33:392–406. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McCubrey JA, Milella M, Tafuri A, Martelli
AM, Lunghi P, Bonati A, Cervello M, Lee JT and Steelman LS:
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
Curr Opin Investig Drugs. 9:614–630. 2008.PubMed/NCBI
|
|
23
|
Kim D, Sun M, He L, Zhou QH, Chen J, Sun
XM, Bepler G, Sebti SM and Cheng JQ: A small molecule inhibits Akt
through direct binding to Akt and preventing Akt membrane
translocation. J Biol Chem. 285:8383–8394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li B, Ren H, Yue P, Chen M, Khuri FR and
Sun SY: The novel Akt inhibitor API-1 induces c-FLIP degradation
and synergizes with TRAIL to augment apoptosis independent of Akt
inhibition. Cancer Prev Res (Phila). 5:612–620. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ohori M, Kinoshita T, Okubo M, Sato K,
Yamazaki A, Arakawa H, Nishimura S, Inamura N, Nakajima H, Neya M,
et al: Identification of a selective ERK inhibitor and structural
determination of the inhibitor-ERK2 complex. Biochem Biophys Res
Commun. 336:357–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Batista LF, Roos WP, Christmann M, Menck
CF and Kaina B: Differential sensitivity of malignant glioma cells
to methylating and chloroethylating anticancer drugs: p53
determines the switch by regulating xpc, ddb2, and DNA
double-strand breaks. Cancer Res. 67:11886–11895. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boult J, Roberts K, Brookes MJ, Hughes S,
Bury JP, Cross SS, Anderson GJ, Spychal R, Iqbal T and Tselepis C:
Overexpression of cellular iron import proteins is associated with
malignant progression of esophageal adenocarcinoma. Clin Cancer
Res. 14:379–387. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Anadol E, Kanca H, Yar AS, Helvacioğlu F,
Menevşe S, Calgüner E and Erdoğan D: Prostaglandin F receptor
expression in intrauterine tissues of pregnant rats. J Vet Sci.
15:125–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brown KK and Toker A: The phosphoinositide
3-kinase pathway and therapy resistance in cancer. F1000Prime Rep.
7:132015. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Y, Kaiser CE, Frett B and Li HY:
Targeting mutant KRAS for anticancer therapeutics: A review of
novel small molecule modulators. J Med Chem. 56:5219–5230. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Britten CD: PI3K and MEK inhibitor
combinations: Examining the evidence in selected tumor types.
Cancer Chemother Pharmacol. 71:1395–1409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cox AD, Fesik SW, Kimmelman AC, Luo J and
Der CJ: Drugging the undruggable RAS: Mission possible? Nat Rev
Drug Discov. 13:828–851. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baines AT, Xu D and Der CJ: Inhibition of
Ras for cancer treatment: The search continues. Future Med Chem.
3:1787–1808. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Takashima A and Faller DV: Targeting the
RAS oncogene. Expert Opin Ther Targets. 17:507–531. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gysin S, Salt M, Young A and McCormick F:
Therapeutic strategies for targeting ras proteins. Genes Cancer.
2:359–372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Watanabe T, Kobunai T, Yamamoto Y, Matsuda
K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H and Eshima K:
Differential gene expression signatures between colorectal cancers
with and without KRAS mutations: Crosstalk between the KRAS pathway
and other signalling pathways. Eur J Cancer. 47:1946–1954. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Steelman LS, Chappell WH, Abrams SL, Kempf
RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F,
Mazzarino MC, et al: Roles of the Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity
to therapy-implications for cancer and aging. Aging (Albany NY).
3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ye Q and She QB: Integration of AKT and
ERK signaling pathways in cancer: Biological and therapeutic
implications. J Pharmacol Clin Toxicol. 1:10092013.
|
|
42
|
Morrow CJ, Gray A and Dive C: Comparison
of phosphatidylinositol-3-kinase signalling within a panel of human
colorectal cancer cell lines with mutant or wild-type PIK3CA. FEBS
Lett. 579:5123–5128. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mut M, Lule S, Demir O, Kurnaz IA and
Vural I: Both mitogen-activated protein kinase (MAPK)/extra
ellular-signal-regulated kinases (ERK) 1/2 and
phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate
activation of E-twenty-six (ETS)-like transcription factor 1
(Elk-1) in U138 glioblastoma cells. Int J Biochem Cell Biol.
44:302–310. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Honda M, Kanno T, Fujita Y, Gotoh A,
Nakano T and Nishizaki T: Mesothelioma cell proliferation through
autocrine activation of PDGF-ββ receptor. Cell Physiol Biochem.
29:667–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ragusa M, Statello L, Maugeri M, Majorana
A, Barbagallo D, Salito L, Sammito M, Santonocito M, Angelica R,
Cavallaro A, et al: Specific alterations of the microRNA
transcriptome and global network structure in colorectal cancer
after treatment with MAPK/ERK inhibitors. J Mol Med (Berl).
90:1421–1438. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dirican A, Atmaca H, Bozkurt E, Erten C,
Karaca B and Uslu R: Novel combination of docetaxel and
thymoquinone induces synergistic cytotoxicity and apoptosis in
DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.
Clin Transl Oncol. 17:145–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Doghman M and Lalli E: Efficacy of the
novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical
model of adrenocortical carcinoma. Mol Cell Endocrinol.
364:101–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim JK and Diehl JA: Nuclear cyclin D1: An
oncogenic driver in human cancer. J Cell Physiol. 220:292–296.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Toulany M, Kehlbach R, Florczak U, Sak A,
Wang S, Chen J, Lobrich M and Rodemann HP: Targeting of AKT1
enhances radiation toxicity of human tumor cells by inhibiting
DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther.
7:1772–1781. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Asakura T and Ohkawa K: Chemotherapeutic
agents that induce mitochondrial apoptosis. Curr Cancer Drug
Targets. 4:577–590. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hong S, Hwang I, Lee YS, Park S, Lee WK,
Fernandes-Alnemri T, Alnemri ES, Kim YS and Yu JW: Restoration of
ASC expression sensitizes colorectal cancer cells to genotoxic
stress-induced caspase-independent cell death. Cancer Lett.
331:183–191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nakagawa Y, Iinuma M, Naoe T, Nozawa Y and
Akao Y: Characterized mechanism of alpha-mangostin-induced cell
death: Caspase-independent apoptosis with release of endonuclease-G
from mitochondria and increased miR-143 expression in human
colorectal cancer DLD-1 cells. Bioorg Med Chem. 15:5620–5628. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tan BJ and Chiu GN: Role of oxidative
stress, endoplasmic reticulum stress and ERK activation in
triptolide-induced apoptosis. Int J Oncol. 42:1605–1612.
2013.PubMed/NCBI
|
|
55
|
Takuwa N and Takuwa Y: Regulation of cell
cycle molecules by the Ras effector system. Mol Cell Endocrinol.
177:25–33. 2001. View Article : Google Scholar : PubMed/NCBI
|
